Profile cover photo
Profile photo
Scott Matusow
frustrated social commentator, people are getting more and more stupid and mean
frustrated social commentator, people are getting more and more stupid and mean
About
Posts

Post has attachment

Post has attachment

Post has attachment

Post has attachment

Post has attachment
In this audio webinar, Danny Cohen and I explain why we are bullish on Calithera Biosciences (CALA). We go over the technology, current data set, upcoming catalysts, and why we believe a deal with $BMY is near to come. We also refer to the recent $CITI analyst coverage and discuss why we believe the coverage is in great part a distortion of the facts. We also talk about why we think CALA'S platform will work well with $BMY's anti PD-1 (Opdivo), nivolumab. Calithera's approach along with Bristol's Opdivo in combination which may provide a viable and highly efficacious treatment for patients suffering from Triple Negative Breast Cancer. This would be good news for patients suffering from this form of breast cancer a long with investors staking a claim in Calithera at the current stock price range. We think Calithera has a higher chance at success than most investors and traders realize at this time in addition to the fact that we have also been hearing that a partnership with Bristol Myers could be upcoming sooner than later. The audio is about 30 minutes in length and contains our scientific/financial thesis and reasoning for being bullish on Calithera.

Post has attachment

Post has attachment
Video: Immunotherapy Explained Part 2 - NK Cell Biology http://stockmatusow.com/immunotherapy-explained-part-2-nk-cell-biology $AFMD $KITE $JUNO $AMGN $ADAP $ADRO #immunotherapy #Oncology

Post has attachment

Post has attachment
Immunotherapy + Affimed Explained Part 1 @turdcapital and myself break down immunotherapy in this 3 part series. $AFMD $JUNO $KITE $ADAP #Immunotherapy

Post has attachment
Wait while more posts are being loaded